Overuse of scans, transfusions, and the length of time on anticoagulants received attention in the latest round of recommendations presented Monday, as part of the initiative across medicine to improve patient care with an eye toward controlling costs.
Hematologists received recommendations about how long to use anticoagulants, when to transfuse sickle cell patients and when to perform surveillance scans in patients with early-stage chronic lymphocytic leukemia (CLL), as the American Society of Hematology (ASH) issued its second list of tests and treatments that should be questioned under the Choosing Wisely initiative.
This year’s list was announced at the start of the 2014 Annual Meeting of ASH, which concludes today in San Francisco, California. The first round of recommendations, numbers 1-5, were announced December 4, 2013; details of recommendations 6-10 were presented at a session Monday.
Choosing Wisely is the initiative of the American Board of Internal Medicine Foundation that asks each specialty to identify tests or treatments that might be overused and unnecessary, with potential harm to patients. While saving healthcare dollars is not the only consideration of Choosing Wisely, its efforts will have that effect if patients and their doctors are more judicious in their medical decisions.
The 2014 ASH Choosing Wisely recommendations are:
Reference
Hicks LK, Bering H, Carson KR et al. Five hematologic tests and treatments to question. Hematology 2014; 2014: 599-60
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bimekizumab Shows Promising 52-Week Safety and Efficacy in Psoriatic Arthritis
May 3rd 2024Promising results presented at the Academy of Managed Care Pharmacy 2024 annual meeting support the safety and efficacy of bimekizumab treatment in patients with active psoriatic arthritis who had previously shown inadequate response or intolerance to tumor necrosis factor inhibitors.
Read More